Uncategorized

After gaining market share during the Philips recall, Resmed can keep growing by stimulating demand through marketing initiatives and new products, William Blair analysts wrote.

Mass.-based Seismic Therapeutic secured a new investor in Bessemer Venture Partners and $121 million in its Series B round as it looks to push its two lead candidates into the clinic.

The acquisition of the freestanding emergency departments comes after HCA announced it was investing billions to expand its emergency and high acuity service lines.

The Ohio-based health system struggled financially during its fiscal year 2022. However, rising patient demand has cut the nonprofit’s operating losses.

In the latest example of major pharma now entering AI collaborations or using AI-based tools, AstraZeneca’s deal with Absci will aim to produce an oncology candidate.

The FDA labeled BD’s safety notice as a Class I event. The warning comes amid several actions from the agency on the safety of syringes.

The acquisition will give Roche access to Carmot’s clinical portfolio of three GLP-1 receptor agonists, placing it squarely in the middle of the competition to treat overweight and obesity.

The European Medicines Agency is seeking additional information from the makers of GLP-1 drugs as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class.

Lilly’s Jaypirca (pirtobrutinib) can now be used to treat chronic lymphocytic leukemia or small lymphocytic leukemia that had progressed from at least two prior lines of therapy, in addition to its previously-approved indications.

Johnson & Johnson’s AI investments include a research facility in San Francisco and a data science workforce of approximately 6,000 employees.